Eventide Asset Management LLC Has $48.33 Million Stake in STERIS plc $STE

Posted by Brenda Bartman on Jun 14th, 2026

Eventide Asset Management LLC increased its holdings in shares of STERIS plc (NYSE:STE – Free Report) by 8.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 190,483 shares of the medical equipment provider’s stock after acquiring an additional 15,416 shares during the period. Eventide Asset Management LLC’s holdings in STERIS were worth $48,326,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Nordea Investment Management AB boosted its holdings in STERIS by 259.0% during the fourth quarter. Nordea Investment Management AB now owns 51,602 shares of the medical equipment provider’s stock worth $13,165,000 after purchasing an additional 37,228 shares during the last quarter. Dimensional Fund Advisors LP raised its position in STERIS by 9.4% during the third quarter. Dimensional Fund Advisors LP now owns 1,039,351 shares of the medical equipment provider’s stock worth $257,157,000 after acquiring an additional 89,250 shares in the last quarter. Legal & General Group Plc lifted its stake in STERIS by 5.3% in the third quarter. Legal & General Group Plc now owns 693,116 shares of the medical equipment provider’s stock valued at $171,505,000 after acquiring an additional 34,981 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in STERIS by 40.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 633,530 shares of the medical equipment provider’s stock valued at $160,613,000 after acquiring an additional 183,680 shares during the last quarter. Finally, Groupama Asset Managment acquired a new stake in STERIS in the third quarter valued at $1,163,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on STE shares. Weiss Ratings cut shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Piper Sandler reiterated an “overweight” rating and issued a $270.00 price target on shares of STERIS in a research note on Thursday, May 21st. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Finally, KeyCorp cut their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Check Out Our Latest Analysis on STE

Insider Transactions at STERIS

In other STERIS news, CEO Daniel A. Carestio sold 1,374 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $212.00, for a total value of $291,288.00. Following the sale, the chief executive officer owned 63,647 shares of the company’s stock, valued at approximately $13,493,164. This trade represents a 2.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the sale, the director directly owned 38,964 shares in the company, valued at approximately $8,163,347.64. This represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 5,909 shares of company stock worth $1,257,083 over the last quarter. Corporate insiders own 1.07% of the company’s stock.

STERIS Price Performance

Shares of STE opened at $207.50 on Friday. The firm has a market capitalization of $20.25 billion, a PE ratio of 26.17 and a beta of 0.93. The company’s 50-day moving average is $216.08 and its 200-day moving average is $237.38. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54.

STERIS (NYSE:STE – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. STERIS’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities analysts forecast that STERIS plc will post 11.18 EPS for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s dividend payout ratio is presently 31.78%.

About STERIS

(Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.